Physician profile
Frank Haraf
NPI 1174584262
$1,025.41
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $82.68 · 2021: $156 · 2022: $230 · 2023: $82.04 · 2024: $99.47 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $199.81 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $182.85 | 2019-2021 | |
| Pfizer INC. | $168.93 | 2019-2025 | |
| Corium, LLC | $96.81 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $71.75 | 2019-2025 | |
| Neos Therapeutics, LP | $55.99 | 2021 | |
| Ironshore Pharmaceuticals INC. | $47.68 | 2019 | |
| Cranial Technologies, INC | $42.49 | 2019-2020 | |
| Sobi, INC | $36.46 | 2022 | |
| Glaxosmithkline, LLC. | $31.29 | 2022 | |
| Verrica Pharmaceuticals INC. | $21.07 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $19.81 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.68 | 2025 | Jornay Pm |
| Tolmar, INC. | $16.66 | 2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $15.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Haraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.